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Abstract
Objectives—To conduct a within cohort assessment of risk factors for incident AIDS defining
cancers (ADC) and non-ADC (NADC) within the Australian HIV Observational Database
(AHOD).
Methods—2181 AHOD registrants were linked to the National AIDS Registry/National HIV
Database NAR/NHD and the Australian cancer registry to identify those with a notified cancer
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diagnosis. Included in the current analyses were cancers diagnosed after HIV infection. Risk
factors for cancers were also assessed using logistic regression methods.
Results—139 cancer cases were diagnosed after HIV infection among 129 patients. More than
half the diagnoses (n=68, 60%) were ADC, of which 69% were KS and 31% NHL. Among the
NADC, the most common cancers were melanoma (n=10), lung cancer (n=6), and 5 cases each of
Hodgkin’s lymphoma and anal cancer. Over a total of 21021 person years (PY) of follow-up since
HIV diagnosis, the overall crude cancer incidence rate for any cancer was 5.09/1000 PY. The
overall rate of cancers decreased from 15.9/1000 PY (95%CI: 9.25-25.40/1000) for CD4 counts
below 100 cells/μL to 2.4/1000 PY (95%CI: 1.62-3.39/1000) for CD4 counts above 350 cells/μL.
Lower CD4 cell count and prior AIDS diagnoses were significant predictors for both ADC and
NADC.
Conclusion—ADC remain the predominant cancers in this population, although NADC rates
have increased in the more recent time period. Immune deficiency is a risk factor for both ADC
and NADC.
Keywords
HIV/AIDS; cancer; antiretroviral treatment; cohort
Introduction
Historically three cancers in HIV positive patients have been designated as AIDS defining
cancers, Kaposi’s Sarcoma (KS), non-Hodgkin’s lymphoma (NHL) and cervical cancer. The
incidence of several other cancers has also been reported to be elevated in HIV positive
patients. These include many infection related cancers, such as human papillomavirus
(HPV) associated cancers, Hodgkin’s lymphoma (HL), and liver and stomach cancer (1-3).
The extent to which lifestyle factors such as smoking and alcohol use, or immune deficiency
contributes to these increased rates is still under debate (1, 4). Since the introduction of
effective combination antiretroviral therapy (cART), the incidence of AIDS-defining
malignancies (ADC) has declined, although they remain elevated compared with rates of
these cancers in the general population (5-7). It is less certain, if a similar decrease in
incidence has occurred post-cART for many of the other non-ADC (NADC) (5, 7).
A large national data linkage study conducted in Australia, linking the national HIV and
AIDS registers to the national cancer registry, reported a dramatic decline in KS and NHL
from pre to post-cART (5). Large declines in NHL and KS have also been demonstrated in
Switzerland (7), Italy (8) and the US since the introduction of cART (2, 9). Among the
NADC, HL incidence was elevated in the early cART era (1996-1999) in Australia,
although it appears to have declined in more recent years (5). In other countries elevated HL
rates in the era of cART have also been reported, yet unlike Australian patterns, incidence
rates have remained unchanged between earlier and later cART years (3). Other commonly
reported NADC that continue to occur at higher rates in HIV positive patients during cART
era are anal cancers (3, 5, 7), and lung cancer (3, 5).
Declining CD4 cell count has an established link with reduced incidence of ADC, in
particular KS and NHL (8, 10-13). However, data regarding immunedeficiency and NADCs
is conflicting, with some studies reporting an association between CD4 cell count and
NADC (14, 15), while others have not (8, 16-18). Infection related NADC in particular have
been demonstrated to be associated with immunedeficiency (1, 14). cART is also
independently associated with a reduced risk of cancer, in particular ADC (11), yet the
impact of HIV therapy on NADC is less is understood.
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In Australia there remains limited data assessing associations between cancer risk and HIV
related factors; notably CD4 cell count and ART use. The objective of this study was to
quantify the rate of incident cancer within the Australian HIV Observational database
(AHOD) and to assess risk factors associated with these cancers.
Methods
AHOD is a prospective cohort study of HIV positive patients under routine clinical care.
AHOD commenced in 1999, and currently has 27 sites around Australia including HIV
tertiary referral centres, HIV specialist general practice clinics and sexual health clinics. Key
clinical data are transferred to the coordinating centre, the Kirby Institute, UNSW, on a six
monthly basis. These data include patient demographics, HIV disease stage, and
antiretroviral treatment history. A detailed description of this cohort has previously been
published (19).
Cancer diagnoses
In 2007, data linkage between the Australian Cancer Database (ACD), and the Australian
National HIV Database (NHD) and National AIDS Registry (NAR) was conducted to
ascertain incident cancer cases among HIV positive Australians. The linkage procedures
between the ACD and the HIV/AIDS registries have been described in detail previously (5).
Briefly, the ACD included all incident invasive cancers diagnosed in Australian residents
since 1982 (up to 2005), excepting nonmelanoma skin cancer. Date of diagnosis and
ICDO-3 and ICD10 codes for tumour topography and morphology were obtained for
matched records. Records were linked based on two-by-two name code (first two letters of
surname followed by first two letters of first name) sex and date of birth. These are the
identifiers that are routinely collected for HIV positive patients in Australia.
The AHOD cohort was subsequently linked to the NHD/NAR records. Records were linked
as described above based on two-by-two name code sex and date of birth. AHOD patients
provided informed consent. Approval to link AHOD to the HIV/AIDS register was also
obtained by all relevant Australian jurisdictional health departments and institutional review
boards.
Cancer categorisation
Cancers were determined to have occurred after HIV infection if they satisfied any of the
following three criteria. First, the date of cancer diagnosis occurred after HIV diagnosis.
Second, in the case where date of HIV diagnosis is unknown, if the cancer diagnosis
occurred after enrolment into AHOD. Finally, if participants were receiving cART for at
least 1 month prior to date of cancer diagnosis. Cancers were then categorised as ADC if
they were either KS, NHL or cervical cancers. All other cancers were categorised as NADC.
We also categorised each incident cancer as either infection-related (IR) or non-infection-
related (NIR). Included as infection-related cancers were all cancers that have a known
infectious cause, as well as those possibly or probably associated with an infectious agent.
Examples of these include cancers that are related to Epstein-Barr-Virus (Hodgkin
lymphoma, non-Hodgkin lymphoma, nasopharynx), human herpesvirus 8 (HHV-8; KS);
HPV (cervix, vagina, penis, anus, oral cavity and pharynx); possibly HPV related (non-
melanoma skin cancer, oesophagus, larynx, eye); Hepatitis B and C (liver) and helicobacter
pylori (stomach) (1, 20), schistosoma haemotobium (blood fluke) (bladder) (20), and
leukaemia, which was similarly elevated in two immune suppressed populations (organ
transplant recipients and HIV positive patients)(1), possibly explained by infection with an
unknown organism (21).
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Patient characteristics (age, sex, mode of HIV exposure, CD4 cell count, and HIV viral load,
and prior AIDS, antiretroviral treatment (ART)) at the time of diagnosis were described for
all cancers overall and by ADC and NADC categories.
For participants with known HIV positive dates, crude incidence rates were calculated from
HIV positive diagnosis to the first cancer, and for KS, NHL and NADC. Age standardised
rates were calculated by calendar periods (≤1992, 1993-1996, 1997-1999, and ≥2000), and
incidence rate ratios were also calculated for calendar periods (reference group ≥2000).
Crude rates were also determined for time updated CD4 category cells/μl (<100, 100-199,
200-349, and 350+). All patients were censored on 31st of December 2005 (last date for
which cancer diagnoses were available). Person-years (PY) were calculated from first
positive date to first cancer diagnosis, death or last follow-up visit.
Risk factors were assessed for NADC and ADC using poisson regression methods. Key a
priori covariates assessed were age, CD4 category, HIV viral load, and prior AIDS (all
assessed as time updated). Factors with p-value < 0.05 in univariate analyses were then
assessed in multivariate analyses using forward stepwise regression methods. All analyses
were conducted using STATA version 11 (STATA Corporation, College Station, Texas,
USA).
Results
A total of 139 linked cancers (n=129 patients) were identified in the 2181 AHOD
registrants. Table 1 lists all cancers types diagnosed, and whether they were infection or non
infection related. 88 cancers (63%) were ADC, of which 61 (69%) were KS, and the
remaining 27 (31%) were NHL. Among the NADC, the most common cancers were
melanoma (n=10), lung cancer (n=6), and 5 cases each of Hodgkin lymphoma and anal
cancer. The majority (78%) of all cancers were infection-related.
All but one of the cancers was diagnosed in males. The median age at cancer diagnosis was
43 years (Interquartile range (IQR):37-52), and was slightly lower for ADC (median: 41;
IQR: 36-49) compared with NADC (median: 50; IQR: 39-56). Similarly, the median age at
cancer diagnosis was lower for IR (median: 43; IQR: 37-51) compared with NIR cancers
(median: 49; IQR: 38-57) (Table 2).
Incidence rate
Among the 2181 AHOD patients, 1793 had a recorded date of HIV diagnosis, including 107
of the 129 individuals diagnosed with cancer. Among these patients, there was total of
21021 person years of follow-up since the date of HIV diagnosis, yielding an overall crude
cancer incidence rate of 5.09/1000 person years. Table 3 reports the age standardised cancer
rates by calendar periods, and incidence rate ratios by KS, NHL and non-AIDS defining
cancers. Cancer incidence was greatest during the period 1993 to 1996 for all cancers
(5.43/1000 PY 95%CI: 3.54-8.05) and for KS (2.85/1000 PY 95%CI: 1.51-4.83). The rate of
NHL was greatest during 1997 to 1999 (1.44/1000 PY 0.54-3.01), while for NADC the rate
was the greatest in the most recent calendar period (2.15/1000, PY 95%CI 1.37-3.31).
Compared to the latest calendar period (2000 onwards) the only standardised incidence rate
ratios which were significantly reduced were for NHL and NADC rates prior to 1992
(Incidence rate ratio (IRR): 0.38 95%CI: 0.09-0.95; and IRR: 0.13, 95%CI 0.03-0.30
respectively).
Crude cancers rates also decreased with increasing CD4 cell count category for all cancers,
from 15.9/1000 PY (95%CI: 9.25-25.40/1000 PY) for CD4 counts below 100 cells/μL to
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2.0/1000 PY (95%CI: 1.15-3.17/1000 PY) for CD4 counts above 500 cells/μL. Similar
decreasing trends were observed for KS, NHL and NADC overall (Figure 1).
Predictors of ADC
In univariate analyses, not receiving ART (p=0.040), lower CD4 cell count category
(p<0.001), detectable (>400 copies/ml) HIV viral load (p<0.001), and having a prior AIDS
diagnosis (p<0.001) was significantly associated with ADC diagnoses (Table 4). These
factors remained significant in multivariate analyses.
Predictors of NADC
In univariate analyses, increasing age, having a prior AIDS diagnosis and low CD4 cell
count were significantly associated with an increased risk of an NADC diagnosis (Table 5).
In multivariate analyses, the independent risk factors for a NADC diagnosis were increasing
age (p<0.001) and having a prior AIDS diagnosis (p=0.004).
Discussion
AIDS-defining cancers were the most common cancers diagnosed in a contemporary cohort
of HIV positive Australians. Nonetheless, crude rates of NADC diagnosed appeared to
increase in the most recent calendar period. Among the NADC, melanoma and lung cancer
were the most common, followed by HL and anal cancer. The rates of cancer decreased as
CD4 cell counts increased. This was observed for cancers overall, for ADC and NADC, and
for individual cancers such as KS and NHL.
Similar findings have been reported in other studies. In the Swiss HIV Cohort Study
(SHCS), the incidence of all ADC and NADC declined in the later cART era. Even NADC
that appeared to increase in incidence in the early cART era, began to decline in the later
periods, such as anus, liver and nonmelanoma skin cancer. In Australia, while melanoma
risk overall has previously been reported as slightly higher in HIV positive patients
compared to the general population (22), more recent findings indicate a significantly
decreased risk in HIV positive patients compared to the general population in the later cART
era (5). Lung cancer remains raised in HIV positive patients, despite a decline in risk from
the pre-cART to late cART era (5). This may in large part be due to increased smoking rates
among men who have sex with men (the group overwhelmingly represented in the HIV
epidemic); they are reported to be two-fold greater than the general population (42% versus
23%)(23). Although also elevated compared to the general population, cancer of the anus
remained stable throughout the entire cART era, with little evidence of a decline (5).
More advanced HIV disease defined by either low CD4 cell count or prior AIDS diagnosis,
was an independent risk factor for both ADC and NADC in our study. Although some
studies have reported no significant association between decreasing CD4 cell count and
increased risk of NADC (6, 8, 16-18), this might at least in part be explained by including
cancers that are not thought to be infection related. In a previous analysis investigating
cancers in the TREAT Asia HIV Observational Database (TAHOD), declining CD4 cell
count was significantly associated with an increased of infection related cancers, but not for
non-infection-related cancers (14). In the current study, prior AIDS was a significant
independent predictor of NADC, although CD4 cell count was not. It is possible that
grouping all NADC together may attenuate any CD4 associations that may exist for
individual cancers. However, we were underpowered to investigate individual NADC (15).
The low risk of NADC by CD4 count, in particular for CD4 counts below 100 cells/μl
(Figure 1) may in part be explained due to competing risks, where patients have died due to
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other HIV related events. This may also in part explain low rates of NADC pre-1992 (Table
3).
In our study, cART use was significantly protective against ADC risk, although this was not
the case for NADC. Likewise in the Swiss HIV Cohort Study there was a significantly lower
risk of ADC in cART users (HR 0.26, 95%CI: 0.20-0.33) compared with non-cART users
(11). In the Chelsea and Westminster cohort, cART use was associated with an increased
risk of NADC (15). We may not have seen a significant association between cART use and
risk of NADC due to relatively low numbers of NADC in our analysis. Alternatively, CD4
count was time updated in our analysis, which may have taken into account any effect of
cART use.
Unsurprisingly, ageing was significantly associated with all cancers; NADC in particular. As
result of effective cART, patients are now living longer, and are therefore at increased risk
of many age associated comorbidities including non-AIDS cancers. In the Swiss and Italian
studies, the increased incidence of NADC in the era of cART was largely explained by
ageing of HIV positive patients (7, 8). Increasing age was also associated with an increased
risk of NADC in Asia (24).
There are some limitations to this study. First, we were limited by the number of events in
this cohort. Our event rate is similar to that reported in other studies, but overall these are
small numbers, and we were therefore unable to assess the risk of individual cancers. For
instance, we identified only four cases of anal cancer which is now the most common non-
AIDS defining cancer among the predominantly gay male population of HIV-positive
Australians (5). Longer follow-up and larger numbers in the cohort are required. Second,
linkage was based on two-by-two name code, date of birth and sex, which may affect the
sensitivity of the linkage and cancer ascertainment. A pilot study previously conducted by
our group, linking NSW AHOD patients to the state births deaths and marriages registry
using two by two name code, date of birth, and sex, demonstrated a very high sensitivity of
99.8% and a specificity of 81% (unpublished data). If similar rates apply to our current
linkage study, then this would result in an under-ascertainment of true cancers. Finally, we
were unable to assess behavioural risk factors for cancer such as smoking and alcohol use.
In summary, we found both ADC and NADC are strongly associated with
immunedeficiency. Further, there appears to be some evidence of increasing numbers of
NADC most likely due to ageing. Longer follow-up will be required to investigate
individual or rarer cancers in the future.
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Table 1
Incident cancers diagnosed by infection 406 related status
Infection related* N Not infection related N
KS 61 Bone 1
NHL 27 Brain 1
HL 5 Lung 6
Anus 5 Colon 1
Lip 3 Mesothelioma 1
Liver 1 Oesophagus 2
Tongue 1 Kidney 2
Salivary 1 Melanoma 10
Gallbladder 1 Prostate 3
Stomach 2 Testis 3
Leukemia 1 Unknown 1
Total (%) 108 (78) Total (%) 31 (22)
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